(Q73531787)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

J P Lattanzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

A L Hanlon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

G E Hanks

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 June 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Radiation Oncology Biology Physics

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

569-573

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Prostate Specific Antigen in the Management of Patients with Localized Adenocarcinoma of the Prostate Treated with Primary Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Prostate-specific antigen and radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900100-4

7 January 2021

10.1016/S0360-3016(97)00100-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9231681%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference